New one-year data presented at the International Federation of Psoriasis Associations (IFPA) Conference 2024 showed that tildrakizumab (Illumetri, Almirall) was effective at restoring and maintaining wellbeing of patients with moderate-to-severe psoriasis. 

Researchers for the POSITIVE study reported that tildrakizumab showed effectiveness as early as 16 weeks into treatment and maintained the benefit out to one year, according to a press release. At one year, 6 out of 10 patients reported PASI ≤1 response. Tildrakizumab was also safe, with no new signals emerging, consistent with prior research. The improvements and skin clearance were particularly pronounced in sensitive areas (scalp, nail, palms/soles) and for high-burden symptoms such as itching, pain, joint pain, and fatigue.

“The impact of psoriasis on patients’ wellbeing cannot be overstated. It affects their overall health, psychological state, and social life," said Prof. Dr. Ulrich Mrowietz, of the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kiel, in the news release. "The interim results from the POSITIVE study are promising, they demonstrate that treatment with tildrakizumab restores patients’ well-being within 16 weeks and maintains it for at least one year. Additionally, significant improvements are observed in skin condition, high-burden symptoms, and sensitive areas. This underscores tildrakizumab’s potential to alleviate the profound burden of psoriasis on daily life.” 

The POSITIVE study is an ongoing, noninterventional prospective observational real-world evidence study that includes 782 adult patients with moderate-to-severe psoriasis. Researchers will follow patients out to 24 months. 

Source: Almirall press release. June 28, 2024.